<DOC>
	<DOC>NCT02553317</DOC>
	<brief_summary>The study is a phase III, double blind, placebo-controlled, randomized study to evaluate the efficacy and safety of caplacizumab in more rapidly restoring normal platelet counts as measure of prevention of further microvascular thrombosis</brief_summary>
	<brief_title>Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura</brief_title>
	<detailed_description />
	<mesh_term>Purpura, Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura, Thrombotic Thrombocytopenic</mesh_term>
	<criteria>1. Adult male or female ≥ 18 years of age at the time of signing the informed consent form (ICF). 2. Clinical diagnosis of acquired TTP (initial or recurrent), which includes thrombocytopenia and microscopic evidence of red blood cell fragmentation (e.g., schistocytes). 3. Requires initiation of daily PE treatment and has received 1 PE treatment prior to randomization 4. Others as defined in the protocol 1. Platelet count ≥100×10E9/L. 2. Serum creatinine level &gt;200 µmol/L in case platelet count is &gt; 30×10E9/L 3. Known other causes of thrombocytopenia 4. Congenital TTP (known at the time of study entry). 5. Pregnancy or breastfeeding. 6. Subjects who were previously enrolled in a clinical study with caplacizumab and received caplacizumab or for whom the assigned treatment arm is unknown 6. Others as defined in the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>